The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL
Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, talks on the findings of the randomized Phase III ALCANZA trial (NCT01578499) of brentuximab vedotin versus physician’s choice of methotrexate or bexarotene in patients with CD30+ cutaneous T-cell lymphoma (CTCL). Prof. Scarisbrick reports that 120 patients were enrolled. The overall response rate and progression-free survival was found to be significantly higher amongst patients receiving brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
